Medical Marketing and Media - GfK forecast: sharp decline in Vytorin, Zetia
Thursday, November 20th, 2008QUESTIONS OVER the efficacy of Vytorin and Zetia could prompt a sharp pullback on firstand second-line use of the drug, according to a survey of physicians by GfK Market Measures, but docs are taking a wait-andsee approach with the drugs and remain open to new data.
The study found gene…
